Kancera’s FRACTAL study results to be presented at the ESC 2024 Conference

Kancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.

Read More

Phase Ib completed and the recommended phase II dose is set in the ongoing KANDOVA study

Kancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567 in ovarian cancer in combination with carboplatin. The objective...

Read More

Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851


The period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...

Read More

Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment

In connection with the upcoming Interim Report for the first quarter 2024, Kancera AB (publ) provides an operational update regarding KANDOVA, a combined phase Ib/IIa study of KAND567 in ovarian cancer, and reports that: The patient recruitment pace has...

Read More

Kancera appoints new Chief Scientific Officer and extends management team

Kancera AB (publ) today announces that Robert Edfors is appointed as new Chief Scientific Officer and Senior Vice President Clinical Development and that the management team is extended with two new positions.

Read More